Charles River Laboratories International, Inc. (CRL) Stock Price & Analysis
Charles River Laboratories International, Inc. (CRL) fell 1.18% to USD 226.58 as of July 25, 2026 at 01:46 UTC, according to Nexqual real-time market data.
CRL last closed at USD 229.29; the session ranged USD 225.03–231.98 on volume of 382,337 shares. Market capitalization is —, with a 52-week range of USD 144.26–238.85 (NYQ). Source: Nexqual, July 25, 2026 at 01:46 UTC.
Key Statistics (as of July 25, 2026 at 01:46 UTC)
| Price | USD 226.58 |
|---|---|
| Change | ▼ 1.18% (down) |
| Previous Close | USD 229.29 |
| Open | USD 230.23 |
| Day Range | USD 225.03 – 231.98 |
| 52-Week Range | USD 144.26 – 238.85 |
| Volume | 382,337 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (CRL)
Nexqual's technical model rates CRL "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 01:46 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.82 (neutral) |
| vs SMA50 | Above (USD 196.69) |
| MACD | 7.22 (positive) |
Analyst Ratings (CRL)
Wall Street analysts rate CRL "Buy" based on 15 analysts, with a mean price target of USD 230.93 (range USD 135–265), per Nexqual as of July 25, 2026 at 01:46 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 230.93 |
| High Target | USD 265 |
| Low Target | USD 135 |
| Buy / Hold / Sell | 13 / 3 / 1 |
Earnings (CRL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 2.73 |
| Revenue Estimate | $976.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.06 vs est 1.95 ▲ beat |
| 2025-12-31 | USD 2.39 vs est 2.35 ▲ beat |
| 2025-09-30 | USD 2.43 vs est 2.34 ▲ beat |
| 2025-06-30 | USD 3.12 vs est 2.55 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
Financials & Fundamentals (CRL)
| Total Revenue | $4.03B |
|---|---|
| Revenue Growth (YoY) | +1.20% |
| Gross Margin | +34.46% |
| Operating Margin | +15.92% |
| Profit Margin | -4.58% |
| ROE | -5.87% |
| Debt / Equity | 102.55 |
| Current Ratio | 1.36 |
| Total Cash | $191.83M |
| Total Debt | $3.06B |
| Free Cash Flow | $510.02M |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
Financial Health Score (CRL)
Nexqual rates Charles River Laboratories International, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:46 UTC.
| Growth | Mixed — Revenue +1.2% YoY (latest Q), slow |
|---|---|
| Profitability | Solid — Gross margin 34%, operating 16% |
| Balance Sheet | Mixed — $192M cash vs $3.06B debt |
| Cash Flow | Solid — FCF $510M, 13% margin |
| Efficiency | Critical — ROE -6%, ROA 4.3% |
Ownership (CRL)
| Insider Ownership | +0.64% |
|---|---|
| Institutional Ownership | +123.82% |
| Float | 47.65M |
| Short % of Float | +10.43% |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
Leadership (CRL)
Charles River Laboratories International, Inc. is led by Birgit Girshick (age 55), CEO & Director, per Nexqual as of July 25, 2026 at 01:46 UTC.
| CEO & Director | Birgit Girshick (age 55) |
|---|---|
| Corporate Executive Vice President of Corporate Development & Strategy | Joseph W. LaPlume (age 51) |
| Corporate Executive VP & CFO | Glenn G. Coleman (age 57) |
| Corporate Vice President of Investor Relations | Todd Spencer |
| Corporate Senior Vice President, Chief Communications Officer & Government Relations | Amy E. Cianciaruso |
Major Backers & Investors (CRL)
Notable institutional backers of Charles River Laboratories International, Inc. include Harris Associates L.P., FMR, LLC, Invesco, according to Nexqual as of July 25, 2026 at 01:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Harris Associates L.P. | 7.37% |
| FMR, LLC | 7.18% |
| Invesco | 7.01% |
| Fidelity | 4.35% |
| Allspring Global Investments Holdings, LLC | 4.14% |
| Wellington Management | 3.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.12% |
| BlackRock | 9.36% |
| State Street | 3.89% |
| Dimensional Fund Advisors | 3.43% |
Source: Nexqual, July 25, 2026 at 01:46 UTC.
From Charles River Laboratories International, Inc.'s Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
- The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
- This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.
- The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services.
Partnerships
- Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TECH | Bio-Techne Corp | USD 71.6 | ▼ 0.25% |
| IQV | IQVIA Holdings, Inc. | USD 208.05 | ▲ 4.8% |
| COO | The Cooper Companies, Inc. | USD 70.31 | ▼ 0.27% |
| BIO | Bio-Rad Laboratories, Inc. | USD 314.46 | ▲ 2.78% |
| WST | West Pharmaceutical Services, I | USD 328.2 | ▼ 8.43% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:46 UTC. This page is informational and not investment advice.